Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference

A Letter from the CEO: AnnJi’s Steadfast Commitment to the SBMA Community

< International Kennedy’s Disease Newsletter >AnnJi Pharmaceutical Expands International Patient Advocacy Collaboration to Advance AJ201 Phase 3 Clinical Trial

Dr. Christopher Grunseich Featured in Quest Media Interview on SBMA and AJ201

AJ201 Expanded Access Program

FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kennedy’s Disease

AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

Double Triumph: AnnJi Pharma Shines at 2025 Taipei Biotech Award

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

AnnJi Pharmaceutical Co. Announced a Pivotal Partnership Change in the Development and Commercialization of AJ201, a First-in-Class Phase 2 Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy